Compare Novavax Inc (NVAX) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs NEOS S&P 500 High Income ETF — how do they compare? Novavax Inc trades at $12.79 (market cap $1.82B), while NEOS S&P 500 High Income ETF trades at $54.09 (market cap $12.50B). The key difference: NEOS S&P 500 High Income ETF is far larger — about 6.9× Novavax Inc's market cap, and Novavax Inc is more actively traded (6,198,505 versus 3,058,962). Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and NEOS S&P 500 High Income ETF for 58 Days on average.
| NVAX | SPYI | |
|---|---|---|
Market Cap | $1.82B | $12.50B |
Volume | 6,198,505 | 3,058,962 |
Sector | Health | Income / Options Overlay |
52-Week High | $12.56 | $54.42 |
52-Week Low | $6.22 | $47.98 |
Typical Hold Time | 59 Days | 58 Days |
Enterprise Value | $1.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
SPYI trades at $54.095 with a modest 0.16% daily gain, showing bullish technical momentum with strong moving average signals. The ETF maintains consistent monthly dividend distributions around $0.53-0.54 per share, targeting income-focused investors. Recent news highlights SPYI's popularity among retirement portfolios while raising concerns about principal erosion from covered call strategies.
The outlook remains mixed - strong technicals and high yield appeal support near-term stability, but long-term capital preservation risks from the covered call strategy warrant caution. Income investors benefit from consistent distributions, though growth-oriented investors may find the strategy limiting during bull markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
